Hepatology Digest: Your team have done a lot of work on prognosis prediction of chronic liver disease using transient elastography(FibroScan), especially development of hepatocellular carcinoma(HCC), and a LSM(Liver stiffness measurement)-based prediction model(LSPS) has been set up. So whether the current results have proved that FibroScan has advantage in predicting risk of HCC in patients with chronic liver disease? Compared to the Liver stiffness measurement (LSM)，LSPS is a better tool for predicting the HCC risk?

　　《国际肝病》：我们注意到，您在FibroScan预测慢性肝病预后预测方面做了很多工作，特别是HCC风险预测方面，并且建立了相关的预测模型（LSPS）。那么目前结果是否已经证明FibroScan在预测慢性肝病患者HCC风险方面具有优势？肝脏硬度值（LSM）与LSPS比较，哪一个的HCC风险预测能力更好？

　　Prof. Han: Liver stiffness (LSM) value based on FibroScan can predict HCC development risk, but by using our prediction model (in which we add age and sex and viral load), we can predict more accurately the risk of HCC development. It is also easy to use for the clinician in making predictions.

　　韩教授：FibroScan检测的肝脏硬度值能够预测HCC的发生风险，但是我们在FibroScan基础上，增加了年龄、性别和病毒载量，建立了新的HCC风险预测模型。该模型能够更准确地预测HCC风险，并且非常便于临床医生的应用。

　　Hepatology Digest: For HCC risk prediction research, your researches mainly focus on what kind of liver disease? Whether FibroScan can be used in predicting risk of HCC in all cause liver disease patients?

　　《国际肝病》：对于HCC风险预测研究，主要是集中在哪些肝脏病患者？FibroScan可以用于所有肝脏疾病患者的HCC风险预测吗？

　　Prof. Han: In Korea, as well as China, chronic hepatitis B is a major problem, so I have been focusing mainly on hepatitis B. But I have also been working on HCV-related, fatty liver and alcohol-related disease. The model however mainly focuses on hepatitis B-related disease.

　　韩教授：与中国一样，在韩国，慢性乙型肝炎也是主要的健康问题，所以我们的研究主要针对乙型肝炎。但是我们也正在丙型肝炎、脂肪肝和酒精性肝病患者中开展FibroScan的检测。已经建立的基于肝脏硬度值的HCC风险预测模型主要是用于乙型肝炎患者。

　　Hepatology Digest:How long have your team used FibroScan?

　　《国际肝病》：您的团队什么时候开始研究和应用FibroScan的？

　　Prof. Han: I received a government grant for a nine-year project in 2005 focusing on liver cirrhosis and with that grant purchased a FibroScan unit for the first time in Asia. So we have been using FibroScan for more than nine years.

　　韩教授：2005年，我受到政府的支助开展肝硬化的9年研究项目，因此我所在的医院成为亚洲第一个购买FibroScan的单位。至今，我们已经使用FibroScan超过了9年。

　　Hepatology Digest:In addition to the HCC risk prediction, has your team also carried out the other studies on FibroScan?  Would you like introduce the main results?

　　《国际肝病》：除了HCC风险预测外，您的团队针对FibroScan还进行了哪些研究？结果如何？

　　Prof. Han:FibroScan is a very useful screening tool but still not the perfect tool. We wanted to improve accuracy so have tested other markers. Recently, fatty liver has been increasing in incidence in Korea so along with FibroScan, we have a CAP score which measures fatty liver stiffness and is very useful.

　　韩教授：FibroScan是非常有应用价值的筛查工具，但是仍有其可以提高的方面。我们希望提高检测的准确性，所以联合了其他（血清学）标志物。韩国的脂肪肝发生率在持续增高，我们在FibroScan基础上同时使用CAP评分检测脂肪肝患者的肝脏硬度，（避免了肝脏脂肪对肝硬度检测结果的影响）。

　　Hepatology Digest:In the clinical application of FibroScan, would you like share some experience with Chinese doctors?

　　《国际肝病》：在FibroScan的临床应用中，您有哪些经验要和中国的医生分享？

　　Prof. Han:There are many good papers from China now because China has a huge amount of patient data. Comparing Chinese and Korean data, the values seem to be higher in the Chinese data, so we should consider confounding factors that may be affecting FibroScan data. Chinese doctors should be careful when using FibroScan, especially in patients with high ALT levels. Also, in the past, we didn’t consider the difference between fasting measurements and after food, so we may need to focus on some clean data by being aware of confounding factors.

　　韩教授：中国有大量的患者数据，近几年来自中国的优秀研究论文很多。对比中国人群和韩国人群的FibroScan检测数据，中国人群的肝硬度值较高，我们认为这可能是由一些影响FibroScan检测结果的混杂因素的影响。在使用FibroScan时，我们应该特别小心ALT升高对肝硬度值的影响。同时，过去我们认为禁食和餐后检测结果没有差别，（但是现在看来并非如此），我们需要对数据进行分析，辨别出一些影响检测结果的混杂因素。